Healthcare & Life Sciences

RetiSpec

Canada

series-a

Stage

Investors

About

RetiSpec develops hyperspectral retinal scan technology to detect Alzheimer's disease years before symptoms appear by analyzing retinal biomarkers for early, non-invasive diagnosis of neurodegenerative diseases.

Explore RetiSpec's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.